TC BioPharm Holdings PLC

Company Profile

TC BioPharm Holdings PLC had its IPO on 2022-02-11 under the ticker symbol TCBP.

The company operates in the Healthcare sector and Biotechnology industry. TC BioPharm Holdings PLC has a staff strength of 60 employees.

Stock update

Shares of TC BioPharm Holdings PLC opened at $0.5 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.46 - $0.54, and closed at $0.5.

This is a +2.02% increase from the previous day's closing price.

A total volume of 195,185 shares were traded at the close of the day’s session.

In the last one week, shares of TC BioPharm Holdings PLC have slipped by -12.3%.

TC BioPharm Holdings PLC's Key Ratios

TC BioPharm Holdings PLC has a market cap of $4.14 million, indicating a price to book ratio of 137.0788 and a price to sales ratio of 84.9731.

In the last 12-months TC BioPharm Holdings PLC’s revenue was $3.84 million with a gross profit of $3.84 million and an EBITDA of $-11158647. The EBITDA ratio measures TC BioPharm Holdings PLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, TC BioPharm Holdings PLC’s operating margin was -310.08% while its return on assets stood at -78.54% with a return of equity of 0%.

In Q2, TC BioPharm Holdings PLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 188.6%.

TC BioPharm Holdings PLC’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into TC BioPharm Holdings PLC’s profitability.

TC BioPharm Holdings PLC stock is trading at a EV to sales ratio of 84.7761 and a EV to EBITDA ratio of -85.2278. Its price to sales ratio in the trailing 12-months stood at 84.9731.

TC BioPharm Holdings PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$10.95 million

Total Liabilities

$9.16 million

Operating Cash Flow

$-40790.00

Capital Expenditure

$4230

Dividend Payout Ratio

0%

TC BioPharm Holdings PLC ended 2024 with $10.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.95 million while shareholder equity stood at $-25677.00.

TC BioPharm Holdings PLC ended 2024 with $0 in deferred long-term liabilities, $9.16 million in other current liabilities, 397493.00 in common stock, $-33731738.00 in retained earnings and $0 in goodwill. Its cash balance stood at $4.81 million and cash and short-term investments were $4.81 million. The company’s total short-term debt was $981,517 while long-term debt stood at $0.

TC BioPharm Holdings PLC’s total current assets stands at $7.45 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.80 million compared to accounts payable of $882364.00 and inventory worth $0.

In 2024, TC BioPharm Holdings PLC's operating cash flow was $-40790.00 while its capital expenditure stood at $4230.

Comparatively, TC BioPharm Holdings PLC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.5

52-Week High

$18

52-Week Low

$0.418

Analyst Target Price

$

TC BioPharm Holdings PLC stock is currently trading at $0.5 per share. It touched a 52-week high of $18 and a 52-week low of $18. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.54 and 200-day moving average was $2.36 The short ratio stood at 0.07 indicating a short percent outstanding of 0%.

Around 1173.9% of the company’s stock are held by insiders while 523% are held by institutions.